Announced details
Regenerative medicine-related business, and the practical implementation and commercialization of cell-derived components and extracellular particles, including exosomes
The analysis was conducted by 株式会社アズフレイヤ under the guidance of Specially Appointed Professor Ochiya Takahiro (落谷孝広) of the Institute of Medical Science, Tokyo Medical University. Capital, personnel and ordinary business relationships have not been disclosed.
The Institute of Medical Science, Tokyo Medical University is a research institution to which Specially Appointed Professor Ochiya Takahiro (落谷孝広) belongs. 株式会社アズフレイヤ is the external institution that conducted the analysis. Other information, including its location, capital, year of establishment and business activities, has not been disclosed.
The impact is expected to be minor at this time. The company will promptly disclose any matters that arise requiring further disclosure.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Neocella, CrymEX (former name) |
| Counterparty | Institute of Medical Science, Tokyo Medical University, 株式会社アズフレイヤ |
| Counterparty overview | The Institute of Medical Science, Tokyo Medical University is a research institution to which Specially Appointed Professor Ochiya Takahiro (落谷孝広) belongs. 株式会社アズフレイヤ is the external institution that conducted the analysis. Other information, including its location, capital, year of establishment and business activities, has not been disclosed. |
| Relationship with the Company | The analysis was conducted by 株式会社アズフレイヤ under the guidance of Specially Appointed Professor Ochiya Takahiro (落谷孝広) of the Institute of Medical Science, Tokyo Medical University. Capital, personnel and ordinary business relationships have not been disclosed. |
| Applicable area | Regenerative medicine-related business, and the practical implementation and commercialization of cell-derived components and extracellular particles, including exosomes |
| Impact on Business Performance | The impact is expected to be minor at this time. The company will promptly disclose any matters that arise requiring further disclosure. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because analysis by an external institution confirmed that Neocella consists of uniform particle components and meets specifications corresponding to extracellular particles.